Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
1.58M
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
68.4K
-
Shares change
-
+831
-
Total reported value, excl. options
-
$71.8K
-
Value change
-
+$862
-
Number of buys
-
3
-
Number of sells
-
-1
-
Price
-
$1.05
Significant Holders of Evoke Pharma, Inc. - Common Shares (EVOK) as of Q4 2023
10 filings reported holding EVOK - Evoke Pharma, Inc. - Common Shares as of Q4 2023.
Evoke Pharma, Inc. - Common Shares (EVOK) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.4K shares
of 1.58M outstanding shares and own 4.32% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (29.9K shares), GEODE CAPITAL MANAGEMENT, LLC (27.1K shares), Tower Research Capital LLC (TRC) (6.45K shares), UBS Group AG (2.91K shares), BlackRock Inc. (1.47K shares), MORGAN STANLEY (375 shares), NewEdge Advisors, LLC (208 shares), WELLS FARGO & COMPANY/MN (26 shares), Federation des caisses Desjardins du Quebec (2 shares), and Concord Wealth Partners (0 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.